Fosamax is a bisphosphonate (i.e., drug that inhibits bone thinning and deterioration) manufactured and marketed by Merck and approved by the FDA in 1995 primarily to treat and prevent osteoporosis. Since its release, Fosamax has been prescribed to hundreds of millions of individuals, predominately post-menopausal women. In these cases, plaintiffs primarily allege dental or jaw-related injuries including osteonecrosis (ONJ). The latter condition, also referred to as bisphosphonate-induced osteonecrosis ("BONJ"), is alleged to causes the jaw bone to die, resulting in severe pain and, often, significant disfigurement.
Next Liaison Counsel Meeting December 9th, 2024 at 1:30pm in person & Case Management Conference December 16th, 2024 at 1:30 pm by Zoom are adjourned.
Next Liaison Counsel Meeting January 22, 2025 at 1:30pm in person in Courtroom 303 & Case Management Conference January 28, 2025 at 1:30 pm EST via Zoom link provided by the court, unless otherwise notified by the court. Agenda and submission shall be submitted to the court 7 days before the liaison counsel meeting.